Partners

Chiesi Farmaceutici, S.A. has obtained the rights to develop and commercialize dutogliptin in Europe (including Russia and the other members of the Commonwealth of Independent States), Turkey, Tunisia, Egypt, Morocco, Pakistan and Brazil. For more information, please view our news release.

Phenomix retains rights to dutogliptin outside of Chiesi territories.

We intend to maximize the value of our product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building our own sales and marketing force.